Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.

Alexander PG. et al, (2020), Br J Cancer

PROGNOSTIC INTEGRATED IMAGE-BASED IMMUNE AND MOLECULAR PROFILING IN EARLY-STAGE ENDOMETRIAL CANCER.

Horeweg N. et al, (2020), Cancer immunology research

The MLH1 polymorphism rs1800734 and risk of endometrial cancer with microsatellite instability.

Russell H. et al, (2020), Clinical epigenetics, 12

Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.

Roseweir AK. et al, (2020), The journal of pathology. Clinical research

Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas.

León-Castillo A. et al, (2020), The Journal of pathology, 250, 312 - 322

Interpretation of somatic POLE mutations in endometrial carcinoma.

León-Castillo A. et al, (2020), The Journal of pathology, 250, 323 - 335

Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.

Skrede O-J. et al, (2020), Lancet (London, England), 395, 350 - 360

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.

Lau D. et al, (2020), ESMO open, 5

Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage.

Glaire MA. et al, (2019), British journal of cancer, 121

The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.

Crosbie EJ. et al, (2019), Genetics in medicine : official journal of the American College of Medical Genetics, 21, 2390 - 2400

ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE study

Lee LYW. et al, (2019), Cancer Medicine

Hand-foot syndrome is a biomarker of improved survival following treatment with capecitabine.

Jandu H. et al, (2019), Annals of oncology : official journal of the European Society for Medical Oncology, 30 Suppl 4, iv117 - iv118

POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer A phase III randomized study.

Lau D. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37

A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer.

Workel HH. et al, (2019), Cancer Immunol Res, 7, 784 - 796

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM. et al, (2019), Clin Cancer Res, 25, 1087 - 1097

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V. et al, (2019), J Natl Cancer Inst

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E. et al, (2018), Lancet Gastroenterol Hepatol, 3, 635 - 643

Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.

Van Gool IC. et al, (2018), Clin Cancer Res, 24, 3197 - 3203

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.

Temko D. et al, (2018), J Pathol, 245, 283 - 296

Changing Practice Evaluation-Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols-Experience From a Supraregional Center.

Tyrrell HEJ. et al, (2018), Clin Genitourin Cancer, 16, 240 - 244

Load More

Include forthcoming?